/HCA
HCA Healthcare, Inc.
HCA • NYSEHCA • NYSE • Healthcare
$544.41+0.48%+2.61
$544.41+0.48%(+2.61)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
47Neutral
Risk
66Low Risk
Momentum
95Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
41.5%▲0.9pp
Revenue after COGS
Operating
15.8%▲0.9pp
After operating expenses
Net
9.0%▲0.8pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
15.9
Price vs earnings
EV/EBITDA
10.1
Enterprise value
FCF Yield
7.1%
Cash generation
Earnings Yield
6.3%
Inverse of P/E
Capital Efficiency
-22
GoAI Quality ScorePoor
ROEReturn on Equity
-112.6%Weak
ROAReturn on Assets
11.2%Strong
ROICReturn on Invested Capital
18.5%Strong
Financial Health
Current RatioWeak
0.83
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
3.15x
Debt repayment capacity (<3x)
Income QualityStrong
1.86
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| Gross Profit | $31.37B | $28.68B | $25.58B | $23.18B | $22.49B |
| Gross Margin | 41.5% | 40.6% | 39.4% | 38.5% | 38.3% |
| Operating Income | $11.96B | $10.55B | $9.63B | $9.05B | $9.68B |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% |
| EPS | $28.62 | $22.27 | $19.24 | $19.44 | $21.51 |
Average Price Target
$523.92▼ 3.8% Downside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for HCA Healthcare, Inc., the average price target is $523.92, with a high forecast of $635.00 and a low forecast of $425.00. The average price target represents a 3.8% decrease from the current price of $544.41.
Highest
$635.00
Average
$523.92
Lowest
$425.00
Rating Distribution
Strong Buy
0
0%
Buy
30
65%
Hold
14
30%
Sell
2
4%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Mizuho● Maintain
Outperform
2026-02-25UBS● Maintain
Buy
2026-02-23JP Morgan● Maintain
Neutral
2026-02-20Argus Research● Maintain
Buy
2026-02-06Wells Fargo● Maintain
Equal Weight
2026-01-30Keybanc● Maintain
Overweight
2026-01-28Barclays● Maintain
Overweight
2026-01-28RBC Capital● Maintain
Outperform
2026-01-28Cantor Fitzgerald● Maintain
Overweight
2026-01-28Oppenheimer● Maintain
Outperform
2026-01-28Earnings History & Surprises
BEAT RATE
78%
Last 18 quarters
AVG SURPRISE
+8.0%
EPS vs Estimate
BEATS / MISSES
14/4
Last 18 quarters
LATEST EPS
$8.01
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+7.4%
$8.01 vs $7.46
Q4 '25
+20.2%
$6.96 vs $5.79
Q3 '25
+8.7%
$6.84 vs $6.29
Q2 '25
+12.2%
$6.45 vs $5.75
Q1 '25
+1.5%
$6.22 vs $6.13
Q4 '24
+0.8%
$5.03 vs $4.99
Q3 '24
+14.0%
$5.53 vs $4.85
Q2 '24
+18.4%
$5.93 vs $5.01
Q1 '24
+17.2%
$5.93 vs $5.06
Q4 '23
-1.8%
$3.91 vs $3.98
Q3 '23
+1.7%
$4.29 vs $4.22
Q2 '23
+25.4%
$4.93 vs $3.93
No investor questions available.
Latest News
No news available